微小钙化在乳腺导管原位癌诊断中的意义

目的 探讨微小钙化在乳腺导管原位癌(DCIS)X线诊断中的价值.方法 回顾性分析35例DCIS的钼靶X线表现.结果 35例中,钙化31例,占88.6%,其中17例临床触及肿块,占48.6%,14例临床未及乳腺肿块,占40%.钙化形态和导管原位癌分级有统计学关联,线性分支状钙化和泥沙样钙化28例,占钙化病例的90.3%.病理显示钙化27例.结论 微小钙化影对DCIS的诊断具有很高的价值.     

乳腺导管原位癌的全数字化钼靶X线诊断

目的探讨乳腺导管原位癌（BDCIS）的全数字化乳腺钼靶X线征象。方法回顾分析30例经手术及病理检查证实为BDCIS的全数字化乳腺钼靶X线表现。常规摄影双侧乳腺轴位（CC位）及侧斜位（MLO位）摄片。结果 30例中26例有病灶内钙化,其中单纯钙化18例,肿块伴钙化3例,结构扭曲伴钙化5例;3例为单纯肿块,其中,边缘光滑、密度均匀的圆形肿块2例,边缘有毛刺、密度不均匀的类圆型肿块1例;1例为单纯结构扭曲。结论 BDCIS全数字化乳腺钼靶X线表现以钙化为主,还应重视肿块、结构扭曲以及局部非对称致密影等征象。     

乳腺导管原位癌的钼靶X线诊断(附20例报告)

目的 探讨乳腺导管原位癌的钼靶X线征象.方法 分析20例经手术及病理证实的乳腺导管原位癌的钼靶X线表现.常规摄影双侧乳腺轴位(CC位)及侧斜位(MLO位)摄片.结果 20例中,16例钙化,3例单纯肿块,1例为小灶致密影.结论 导管原位癌(DCIS)X线表现以钙化为主,还应重视肿块、小灶致密影等征象.     

数字化X线摄影与磁共振成像在乳腺导管原位癌诊断中的对比应用

目的探讨数字化X线摄影与磁共振成像（magnetic resonance imaging,MRI）在乳腺导管原位癌（ductal carcinoma in situ,DCIS）诊断中的应用价值。方法回顾性分析39例经手术及病理检查证实为DCIS患者的X线及MRI影像学资料。结果 39例中X线摄影诊断正确28例（71.8%）,MRI诊断正确32例（82.0%）。X线摄影结合MRI诊断正确36例（92.3%）。结论 X线摄影与MRI对DCIS的诊断具有重要作用,两者联合应用可提高其诊断准确率。     

微钙化对早期乳腺导管原位癌的诊断价值

 目的 探讨微钙化在乳腺X线摄影筛查中对乳腺导管原位癌(ductal carcinoma in situ,DCIS)的诊断价值.方法 回顾性分析经乳腺X线摄影筛查及组织病理、免疫组化证实存在微小钙化灶的DCIS 58例.参照美国放射学会(ACR)颁布的乳腺病变BI - RADS有关钙化形态和分布的征象描述,记录钙化灶的形态、分布数据.全部病例均对照病理结果.采用Fisher确切概率法检验,探讨钙化形态和导管原位癌分级之间的相关性.结果 微钙化按外观与形态分成3类:(1)线形分支状钙化46例(79％);(2)成簇泥沙样钙化5例(8％);(3)微钙化伴粗大钙化7例(12％).所有58例DCIS患者中,低级别(1级)DCIS 14例(24％),中级别(2级)DCIS 35例(60％),高级别(3级)DCIS 9例(16％).不同级别原位癌的X线摄影钙化方式存在统计学差异(P＜0.01);原位癌分级与病灶内微钙化方式存在一定关联度(r=0.559,P＜0.01).结论 微钙化有助于DCIS的早期检出,其形态外观有助于判别其病理分级,正确认识乳腺X线摄影钙化可提高DCIS的诊断准确性.     

乳腺导管原位癌伴微浸润与导管原位癌的临床病理及X线表现对比分析

目的对比分析乳腺导管原位癌伴微浸润(DCISM)与导管原位癌(DCIS)的X线及临床病理表现及DCISM的预测因子。方法收集2016年1月至2020年7月在青岛大学附属医院经手术病理证实的DCISM及DCIS患者626例,患者术前均接受乳腺X摄影检查。参照乳腺影像报告和数据系统(BI-RADS)标准对DCISM与DCIS患者X线表现进行分类诊断。采用χ²检验或Fisher确切概率法分析DCISM与DCIS患者临床病理及X线表现的差异性,应用单因素和多因素二元logistic回归分析探讨与DCISM相关的危险因素。结果626例患者中,DCISM患者171例,DCIS患者455例。单因素回归分析表明,肿瘤直径≥2.7cm、高核级别、粉刺性坏死、淋巴结阳性、Ki67高表达、雌激素受体及孕激素受体阴性是DCISM的预测因子(P<0.05)。多因素回归分析显示,肿瘤直径≥2.7cm(OR 2.229,95%CI 1.505~3.301,P<0.001)、高核级别(OR 1.711,95%CI 1.018~2.875,P=0.043)、淋巴结阳性(OR 4.140,95%CI 1.342~12.773,P=0.013)是DCISM的独立预测因子(P<0.05)。乳腺X线摄影中,DCIS与DCISM患者的病变类型、有无钙化及钙化分布差异具有统计学意义(χ²分别为17.42、9.65、9.10,P<0.05),17.6%(80/455)的DCIS患者表现为隐匿性病变,49.1%(84/171)的DCISM表现为钙化伴肿块、非对称致密、结构扭曲。团簇状钙化多见于DCIS(41.5%,120/289),而区域性钙化在DCISM中更普遍(35.9%,47/131)。结论乳腺X线摄影表现为钙化性病变及区域性钙化在DCISM中更常见。肿瘤直径≥2.7cm、高核级别、淋巴结阳性是DCISM的独立预测因子。     

全数字化乳腺X线摄影对乳腺导管原位癌的诊断价值

目的探讨全数字化乳腺X线摄影(full-field digital mammography,FFDM)对乳腺导管原位癌的诊断价值。方法回顾性分析52例经穿刺或手术病理证实的乳腺导管原位癌的X线摄影表现。结果以恶性钙化为主要征象32例,钙化表现为微细、多形性,呈簇状、群集或段性分布,其中单纯钙化24例,钙化合并局灶性致密8例;表现为肿块8例,其中3例肿块边缘见毛刺;单纯局灶性致密3例;结构扭曲2例;导管造影显示导管内占位性病变3例;X线无异常发现4例。结论 FFDM可以清晰显示微小钙化、小结节、局灶致密及结构扭曲等征象,尤其对微小钙化敏感,对乳腺导管原位癌的诊断具有重要价值。     

乳腺MRI对导管原位癌及其微浸润的诊断

目的 探讨乳腺MRI对导管原位癌及其微浸润的诊断价值.方法 回顾性分析经手术病理证实的乳腺导管原位癌及导管原位癌伴微浸润病例 13例,所有病例均于术前行动态增强MRI检查,其中 10例同时行钼靶X线检查.结果 MR检查13例病灶中11例表现为非肿块样强化,10例行钼靶X线检查,1例阴性,以BIRADS分级中的4、5级为MR和X线检查的阳性指标,其正确诊断率差异无统计学意义(P=0.353).以病理结果为金标准,MRI界定病灶范围符合10例,高估2例,钼靶X线符合6例,高估2例,低估1例,差异无统计学意义(P=0.277).结论 乳腺MRI对导管原位癌及导管原位癌伴微浸润有其特征性表现,钼靶X线和MR检查相结合能提高早期导管原位癌的检出率及正确诊断率.     

乳腺导管原位癌的影像学评价

乳腺导管原位癌 (ｄｕｃｔａｌｃａｒｃｉｎｏｍａｉｎｓｉｔｕ ,ＤＣＩＳ)也称导管内癌 (ｉｎｔｒａｄｕｃｔａｌｃａｒｃｉｎｏｍａ) ,是指乳腺导管系统内恶性上皮细胞的增殖 ,在镜下 ,其特点是基底膜周围基质无浸润的迹象[1] 。近2 0多年来 ,乳腺Ｘ线摄影技术的应用与发展很快 ,能对微小癌变早期确诊 ,ＤＣＩＳ的发病率急剧上升。现在 ,仅凭乳腺Ｘ线片上的典型异常微小钙化 ,就能提示ＤＣＩＳ的诊断。Ｗｉｎｃｈｅｓｔｅｒ等[2 ] 报道 ,在美国 ,每年新诊断的乳腺癌中 ,12 %～ 15 %为ＤＣＩＳ ,其中 90 %由乳腺摄片发现。ＤＣＩＳ起病隐匿…     

钙化型及非钙化型乳腺导管原位癌的病理分级及免疫组织化学特征

目的 比较X线表现为钙化型和非钙化型乳腺导管原位癌(DCIS)的病理分级和免疫组织化学特征的区别.方法 回顾性分析经手术证实为DCIS的121例患者(124个病灶),根据术前X线表现分为钙化组和非钙化组,分析两组间病理分级及雌激素受体(ER)、人表皮生长因子受体2(HER2)表达情况的区别,并对钙化组病灶分析其钙化特点...     

Mammographic features of ductal carcinoma in situ (DCIS) present on previous mammography.

AIM: To review previous mammograms of women found later to have DCIS and identify features which may have been missed or misinterpreted as benign. METHODS: The previous mammograms of 50 women who developed DCIS were analysed. The mammographic features at diagnosis and on the prior mammograms were compared. RESULTS: 11 (22%) of the previous mammograms were in retrospect abnormal; 5 (45%) of these had previously been assessed for the abnormality. All showed microcalcification. The following features were commoner at diagnosis than on previous films; rod shaped calcification (64 vs. 27%, P = 0.03) and a ductal distribution of calcification (76 vs. 45%, P = 0.05). Predominantly punctate calcification (64 vs. 12%, P = 0.001) and less than 10 calcifications in the cluster (54 vs. 24%, P = 0.05) were more common on the previous films. No difference was found in the frequency of granular calcification, branching calcification, irregularity in density, size or shape of calcification between the two groups. CONCLUSION: Features of DCIS missed on previous mammography include small cluster size, less than 10 calcifications in the cluster, the absence of rod shaped calcifications, the absence of a ductal distribution and the presence of predominantly punctate calcification. Features frequently seen both at diagnosis and on previous films which might have allowed earlier diagnosis were granular calcifications which vary in size, density and shape in an irregularly shaped cluster. Focal clustered calcification deserves aggressive investigation.     

Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography

The purpose of this study was to assess the relationship between functional parameters derived from dynamic MR imaging and the histological findings of breast ductal carcinoma in situ (DCIS) and DCIS with invasive foci, and to evaluate whether these parameters might predict DCIS patient outcome. Two parameters, amplitude A and k₂₁, were determined from multicompartmental pharmacokinetic analyses of dynamic MR mammography in 39 patients with needle biopsy-proven primary DCIS. After surgery, the histological tumor characteristics, including microvessel density (MVD) (anti-CD-34), vascular permeability (anti-VEGF antigen) and histological grade, were evaluated. Histology revealed 27 pure DCIS and 12 DCIS with invasive foci. In pure DCIS, positive correlations between MVD and amplitude A (r=0.56, P<0.0025) and between MVD and k₂₁ (r=0.43, P=0.02) were found. As for histological grade, the differences in both functional parameters of grade 1 versus grade 2 and grade 1 versus grades 2 and 3 combined were significant (P<0.05). No significance was found in the analysis of DCIS with invasive foci. Our results indicated that functional MRI-based parameters might possess the potential to predict the outcome of patients with DCIS. Further study will be needed with larger series over longer periods.     

Nonpalpable ductal carcinoma in situ versus infiltrating carcinoma of the breast--can they be differentiated by mammography?

The radiologic patterns of 193 consecutive women with nonpalpable breast carcinoma were evaluated. The results were correlated with patient age and with the histopathologic diagnosis. Of the 193 women in the study, 135 (70%) were older than 50 years; 102 women had ductal carcinoma in situ, and 67 (62%) of them were over age 50; the remaining 91 women had infiltrating carcinoma, and 73 (80%) of these patients were older than 50 years. Of the 58% of women who presented with microcalcifications, 75% had ductal carcinoma in situ and 25% infiltrating carcinoma. Of the 36% of patients who presented with a mass, 87% had infiltrating carcinoma and 90% were over age 50. Six percent presented with a mass with microcalcifications; 75% of these masses were found to be infiltrating carcinoma. Most of the masses were infiltrating carcinoma, and of these 90% were high-density masses. The small number of masses representing ductal carcinoma in situ were proportionately of low density.     

Extension of ductal carcinoma in situ: histopathological association with MR imaging and mammography.

The purpose of this study is to evaluate the capability of breast MRI (magnetic resonance imaging) and mammography in determining tumor extent and the detectability of ductal carcinoma in situ (DCIS) in association with histopathological features. Thirty women with breast cancer underwent 3D dynamic MRI. Twelve women had pure DCIS and 18 women had DCIS with microinvasion. We analyzed the results of preoperative MRI and mammography with histopathologic results, retrospectively. The mean lesion size was 55.1 mm from the histopathologic results. Twenty-six lesions were detected through the MRI (a sensitivity of 86.7%). MRI depicted eight lesions without mammographically detected microcalcification. In seven cases, MRI showed tumor extent accurately compared with mammography, and the combined diagnosis improved the accuracy of evaluating tumor extent. MRI can complement mammography in guiding surgical treatment of DCIS by providing better assessment of the extent of the lesion.     

钼靶结合MRI对乳腺导管原位癌诊断价值的探讨

目的:分析乳腺导管原位癌的X线及MRI表现,评价钼靶结合MRI对DCIS术前诊断价值。方法:回顾性分析经手术病理证实的乳腺DCIS病例13例,所有病例均于术前行动态增强MRI和钼靶X线检查,同时行免疫组化标记。结果:①将病灶的X线表现分成恶性钙化、中间性钙化和非钙化3组,PR与C-erbB-2在3组中的分布有统计性意义(P<0.05);②13例病灶中11例MR表现为非肿块样强化,以BI-RADS分级中的4、5级为MR和X线检查的阳性指标,其正确诊断率差异无统计学意义(P>0.05)。结论:DCIS的钼靶X线表现可以作为乳腺DCIS的预后因子,乳腺MRI对导管原位癌及导管原位癌伴微浸润有特征性表现,钼靶X线和MR检查相结合能提高早期导管原位癌的检出率及正确诊断率。